To include your compound in the COVID-19 Resource Center, submit it here.

Ono Pharmaceutical sales and marketing update

Ono launched Opdivo nivolumab in Japan to treat unresectable melanoma. The Japanese National Health Insurance (NHI) list

Read the full 172 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE